CAPTRUST Financial Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

CAPTRUST Financial Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-576	Closed	-$84K	–	4741
2022 Q2	$84K	Buy	576 +6	+1%	+$766	﹤0.01%	2347
2022 Q1	$68K	Sell	570 -5	-0.9%	-$624	﹤0.01%	2566
2021 Q4	$79K	Buy	575 +144	+33%	+$18.3K	﹤0.01%	2340
2021 Q3	$60K	Buy	431 +44	+11%	+$5.49K	﹤0.01%	2461
2021 Q2	$38K	Buy	387 +87	+29%	+$7.06K	﹤0.01%	2697
2021 Q1	$21K	Buy	300 +225	+300%	+$18.2K	﹤0.01%	2985
2020 Q4	$6K	Buy	+75	New	+$6.36K	﹤0.01%	2815

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

CAPTRUST Financial Advisors's BHVN Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 576 shares — an estimated $84K sold.

CAPTRUST Financial Advisors first reported a position in BHVN in Q4 2020 and held it in 7 quarters. The position peaked at $84K in Q2 2022. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

CAPTRUST Financial Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
CAPTRUST Financial Advisors sold 576 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $84K.
CAPTRUST Financial Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2020 and held it in 7 quarters.
CAPTRUST Financial Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $84K in Q2 2022.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.